Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
MedPharm expands proteomic capabilities with Olink certification
4+ hour, 56+ min ago (64+ words) Indian Pharma Post MedPharm expands proteomic capabilities with Olink certification The Business of Genomics: Opportunities, Investments, and Innovation in India Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants Implementing a digital transformation in chemical operations to…...
Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone
1+ hour, 37+ min ago (326+ words) Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development of first in class oral obesity drug LX9851. Lexicon received a milestone payment from Novo Nordisk tied to clinical progress for LX9851 in obesity and metabolic disorders. The…...
Roche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate
2+ hour, 11+ min ago (353+ words) Roche has conducted its joint-largest deal of the year so far, licensing a clinical-stage UCN2 (urocortin-2) analog being developed for weight loss by South Korea-based Hanmi Pharm. The Swiss big pharma company is paying Hanmi $190m upfront for HM17321, with development, regulatory, and…...
FDA places clinical hold on Regenxbio’s gene therapy for Hunter Syndrome
1+ hour, 24+ min ago (301+ words) Aug 24 (Reuters) – Regenxbio said on Monday the U.S. FDA has placed its experimental gene therapy for a rare inherited disorder on clinical hold after spinal scans found abnormalities in five study participants, sending its shares down more than 24% in premarket…...
Werewolf Therapeutics merges with Ambros
2+ hour, 59+ min ago (292+ words) The companies are working to advance neridronate toward potential first US Food and Drug Administration (FDA) approval for complex regional pain syndrome type 1 (CRPS-1). The combined entity will operate as Ambros Therapeutics and is expected to trade on Nasdaq under…...
BioTissue Appoints Ophthalmic Industry Leader Chris Calcaterra to Board of Directors
44+ min ago (118+ words) EIN Presswire There were 1,387 press releases posted in the last 24 hours and 484,127 in the last 365 days. BioTissue Appoints Ophthalmic Industry Leader Chris Calcaterra to Board of Directors Chris Calcaterra, Board of Directors, BioTissue Addition Brings Proven Commercial Expertise as BioTissue…...
Global UAV Announces Business Combination Transaction with Nexus Peptide Sciences Inc
5+ hour, 29+ min ago (350+ words) About Nexus Peptide Sciences Inc. Nexus is a private biotechnology company, based in Vancouver, British Columbia. Nexus is developing peptide formulations and delivery systems intended to improve stability, absorption and practical use across metabolic health, recovery and longevity applications. Once…...
Roche Gains Rights to Hanmi Obesity Drug That Reduces Fat, Preserves Muscle
1+ hour, 34+ min ago (476+ words) Hanmi Pharmaceutical’s drug is designed to activate a receptor in skeletal muscle to both increase muscle mass and reduce fat. This engineered peptide gives Roche a clinical-stage asset that addresses a different target than the other obesity drugs in its…...
Four Market Forces: Key life sciences market signals UK investors should watch
7+ hour, 5+ min ago (14+ words) Kalkine Media...
LISTING OF TURBO WARRANTS ISSUED BY MORGAN STANLEY & CO. INTERNATIONAL PLC
4+ hour, 1+ min ago (19+ words) view.news.eu.nasdaq.com NOTICE 2026-08-24 TURBO WARRANTS (Record Id 360837)...